Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.87, issue.2, pp.211-217, 2012. ,
DOI : 10.1158/1078-0432.CCR-07-0815
Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway, Cell Cycle, vol.7, issue.24, pp.3810-3814, 2008. ,
DOI : 10.4161/cc.7.24.7245
PI3K/AKT Mediated P53 Down-Regulation Participates in CpG DNA Inhibition of Spontaneous B Cell Apoptosis, Cellular & Molecular Immunology, vol.6, issue.3, pp.175-180, 2009. ,
DOI : 10.1038/cmi.2009.24
Favorable response of early stage B CLL patients to treatment with IFN-alpha 2, Blood, vol.73, issue.6, pp.1426-1430, 1989. ,
Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD, Blood, vol.95, issue.4, pp.1199-1206, 2000. ,
CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells, European Journal of Immunology, vol.23, issue.5, pp.1218-1222, 1994. ,
DOI : 10.1002/eji.1830240532
Active Toll-like receptor-7 triggering of chronic lymphocytic leukemia B-cells by imiquimod, Leukemia & Lymphoma, vol.87, issue.4, pp.739-781, 2012. ,
DOI : 10.1038/leu.2009.195
Reduced levels of both circulating CD4+CD25+CD127low/neg and CD4+CD8neg invariant natural killer regulatory T cells in stable heart transplant recipients, Clinical & Experimental Immunology, vol.87, issue.1, pp.104-116, 2011. ,
DOI : 10.4049/jimmunol.177.12.8338
B1 cells expressing CXCR3 possibly involved in the control of cardiac allograft rejection could be monitored in peripheral blood Abstract 2nd European Congress of Immunology in Berlin, 2009. ,
Cytotoxic T Cell Reponses Against Immunoglobulin in Malignant and Normal B Cells: Implications for Tumor Immunity and Autoimmunity, Current Pharmaceutical Design, vol.9, issue.23, pp.1889-1903, 2003. ,
DOI : 10.2174/1381612033454333
Immunomodulatory eff ects of ,
Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells, Haematologica, vol.92, issue.9, pp.1279-1281, 2007. ,
DOI : 10.3324/haematol.10975
Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation, International Journal of Cancer, vol.105, issue.5, pp.1132-1143, 2010. ,
DOI : 10.1182/blood-2004-10-3873
Classifi cation, mechanisms of action, and therapeutic [6] applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9 Stimulation of iNOS [7] expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-? B activation, Mediators Infl amm Nitric Oxide, vol.201019, pp.986596138-145, 2008. ,
Imiquimod: mode of action, Br J Dermatol, vol.157, pp.8-13, 2007. ,
Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro, British Journal of Haematology, vol.18, issue.2, pp.181-187, 2004. ,
DOI : 10.1038/bjc.1987.186
The vitamin D3 analog EB1089 [10] induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in Leuk Lymphoma Downloaded from informahealthcare, p.12 ,
Release of interleukin-6 in cultured B-chronic [13] lymphocytic leukaemia cells is associated with both activation and cell death via apoptosis Interleukin-8 induces [14] the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion, Anticancer Res Blood, vol.1987, pp.3953-3959, 1996. ,
A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia, Leukemia, vol.176, issue.1, pp.222-226, 2010. ,
DOI : 10.4049/jimmunol.176.6.3830
Th e immune response [11] modifi er imiquimod requires STAT-1 for induction of interferon, interferon-stimulated genes, and interleukin-6, Antimicrob Agents Chemother, vol.43, pp.856-861, 1999. ,
Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways., Molecular and Cellular Biology, vol.15, issue.4, pp.2207-2218, 1995. ,
DOI : 10.1128/MCB.15.4.2207
faible immunogénicité des cellules leucémiques est une maladie de présentation hétérogène dont l'évolution est liée à certains facteurs pronostiques. L'immunochimiothérapie a permis de progresser dans le traitement de cette pathologie, mais l'identification de nouvelles cibles d'immunothérapie serait souhaitable. Dans ce contexte, la présence de TLR-7 et TLR-9 sur les cellules de LLC est une piste intéressante. L'objectif principal de cette étude était ainsi de préciser les effets in vitro de l'engagement de TLR-7 et TLR-9 sur les cellules tumorales par leur ligands respectifs Imiquimod R837 et ODN CpG M362. Ces effets ont été examinés sur des LLC classées en formes stables ou agressives et/ou selon leur statut mutationnel IgVH. Les cellules séparées de 40 patients ont été cultivées pendant trois jours, avec du milieu seul, de l'acétate phorbolmyristate (PMA) ,